Intrexon Corporation

254 articles about Intrexon Corporation

• 

  BioSpace Movers & Shakers, Jan. 3

  1/3/2020

  Pharma, biotech and life sciences companies boost their leadership ranks with this weeks Movers & Shakers.

• Intrexon To Achieve $175M Cash Goal, Appoints Helen Sabzevari, PhD, As New President And CEO And Will Change Name To Precigen To Reflect Healthcare Focus

  1/2/2020

  Intrexon Corporation (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, announced today that it will refocus the company on healthcare, change its name to Precigen, Inc. and, effective immediately, has appointed Helen Sabzevari, PhD, as President and CEO.

• 

  Intrexon Begins 2020 With a New CEO and Name Change

  1/2/2020

  The company is changing its name to Precigen, Inc. and tapped Helen Sabzevari as its new president and chief executive officer.

• Intrexon Reports Third Quarter 2019 Financial Results

  11/12/2019

  Quarterly GAAP revenues of $23.0 million and net loss attributable to Intrexon of $53.6 million including non-cash charges of $19.5 million

• Intrexon to Announce Third Quarter Financial Results on November 12th

  11/4/2019

  Intrexon's subsidiary Precigen to host conference call to provide business and pipeline updates

• David H. Witte to lead MBP Titan LLC

  9/26/2019

  Former head of IHS Markit Energy, Chemicals and Agribusiness Division to lead company for Intrexon's Methane Bioconversion Platform (MBP)

• ActoBio Therapeutics™ Receives IND Green Light for New Antigen-Specific Immunotherapy Study Aimed at Improving Celiac Patients' Tolerance of Gluten

  8/19/2019

  Celiac Disease is an underserved market with no approved pharmacological therapies

• Intrexon Reports Second Quarter and First Half 2019 Financial Results

  8/8/2019

  Quarterly GAAP revenues of $36.0 million and net loss attributable to Intrexon of $38.8 million including non-cash charges of $8.0 million

• Intrexon to Announce Second Quarter and First Half 2019 Financial Results on August 8th

  8/1/2019

  Intrexon Corporation announced it will release second quarter and first half 2019 financial results after the market closes on Thursday, August 8th, 2019.

• Precigen Announces First Patient Dosed in Phase 1/1b Study of PRGN-3006 UltraCAR-T™ in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or Higher Risk Myelodysplastic Syndrome (MDS)

  6/26/2019

  Milestone represents the first patient dosed with Precigen's transformative non-viral UltraCAR-T therapeutic platform that eliminates ex vivo expansion and reduces manufacturing time to fewer than two days following gene transfer

• Intrexon Corporation and Surterra Wellness Partner in $100mm Deal to Advance Commercial Scale Fermentation-based Cannabinoid Production

  6/18/2019

  Exclusive Global Agreement to Transform Surterra's Ability to Produce Specific Cannabinoids to Meet Growing Demand, Boost Innovation and Product Development

• Intrexon's Subsidiary Precigen to Present at the JMP Securities Life Sciences Conference

  6/13/2019

  Intrexon Corporation and Precigen, Inc. announced their presentation at the JMP Securities Life Sciences Conference in New York.

• Intrexon Announces Advances in Non-Browning GreenVenus™ Romaine Lettuce

  6/3/2019

  Non-Browning Romaine lettuce demonstrates improved shelf life, reducing food waste and is not subject to regulation as a product produced through genetic engineering by the USDA

• Intrexon to Participate in 2019 BIO International Convention

  5/28/2019

  Intrexon Corporation announced the Company and its subsidiaries will participate in the 2019 BIO International Convention June 3-6th in Philadelphia.

• Intrexon to Present at the Bank of America Merrill Lynch 2019 Healthcare Conference

  5/13/2019

  Intrexon Corporation announced Randal J. Kirk, Chairman and Chief Executive Officer, will present at the Bank of America Merrill Lynch 2019 Healthcare Conference in Las Vegas on Wednesday, May 15th, at 3:40 p.m. Pacific Time.

• Intrexon Reports First Quarter 2019 Financial Results

  5/9/2019

  Intrexon Corporation announced its first quarter financial results for 2019.

• Intrexon and Xogenex Present at American Society of Gene and Cell Therapy Annual Meeting

  4/29/2019

  Intrexon Corporation and its majority owned Intrexon Health subsidiary Xogenex, announced that four abstracts will be presented as posters at the American Society of Gene and Cell Therapy Annual Meeting, which will be held April 29 - May 2, 2019, at the Washington Hilton in Washington, D.C.

• Oxitec Signs New Multi-year Development Agreement to Apply 2nd Generation Technology to Control Soybean Looper

  4/16/2019

  Oxitec to develop a safe, self-limiting insect capable of reducing pest populations and reversing insect resistance to biotech traits and chemistries

• Intrexon to Highlight Microbial Cannabinoid Production Platform at the Paradigm Capital Biosynthesis Conference

  4/10/2019

  Intrexon Corporation announced Thomas D. Reed, PhD, Founder and Chief Science Officer, will present at the Paradigm Capital Biosynthesis Conference on April 15, 2019 in Toronto.

• Intrexon Intensifies Focus on Healthcare, Forms Two Units and Streamlines Management

  4/3/2019

  Two therapeutic candidates from Precigen's game-changing UltraCAR-T™ therapeutic platform commencing clinical studies